Aurintricarboxylic Acid Prevents Acute Rethrombosis in a Canine Model of Arterial Thrombosis
- 1 March 1995
- journal article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 15 (3), 359-366
- https://doi.org/10.1161/01.atv.15.3.359
Abstract
Abstract Acute rethrombosis following thrombolytic therapy occurs in 5% to 25% of patients. We evaluated the effect of aurintricarboxylic acid (ATA), a triphenyl dye that blocks von Willebrand factor (vWF) binding to platelet glycoprotein Ib, on arterial reperfusion and acute rethrombosis following fibrinolytic therapy. Primary thrombosis was induced in the femoral arteries of anesthetized dogs by application of anodal current and partial arterial constriction. Blood flow was monitored with an electromagnetic flow probe, and primary thrombosis was considered to have occurred when blood flow was reduced to and remained at zero. Reperfusion was induced by intravenous streptokinase 30 minutes after thrombosis. Streptokinase reduced plasma fibrinogen levels from an average of 144 mg/dL to <5 mg/dL resulting in inhibition of ADP- and epinephrine-induced platelet aggregation ex vivo. Acute rethrombosis following reperfusion occurred within 37±18 (mean±SD) minutes in 89% (16/18) of animals receiving thrombolytic activator treatment. Histological examination of reoccluding thrombi revealed densely aggregated platelets and erythrocytes with no detectable fibrin. In the two other study groups, ATA was infused in conjunction with thrombolytic therapy (10 arteries) or at near completion of acute rethrombosis following fibrinolytic activator treatment (6 arteries). In each case ATA prevented rethrombosis. However, concomitant administration of ATA and thrombolytic therapy delayed restoration of blood flow. ATA had no direct effect on hemodynamics, thrombin time, platelet count, or platelet aggregation response to ADP, epinephrine, or collagen. These data indicate that inhibition of vWF–platelet glycoprotein Ib interaction is effective in preventing acute rethrombosis following thrombolytic therapy. However, the complex paradoxical effects of ATA on platelet activity should be considered when it, or agents of its class, are used as antithrombotics.Keywords
This publication has 18 references indexed in Scilit:
- Mr 6,400 aurin tricarboxylic acid directly activates plateletsThrombosis Research, 1993
- Redefining the role of digoxin in the treatment of atrial fibrillationThe American Journal of Cardiology, 1992
- Recombinant hirudin reduces the incidence of thrombotic occlusion in a canine model of coronary vascular injuryCoronary Artery Disease, 1991
- Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparationJournal of the American College of Cardiology, 1990
- Platelets and Thrombolytic TherapyNew England Journal of Medicine, 1990
- Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model.Journal of Clinical Investigation, 1989
- Tissue-Type Plasminogen ActivatorDrugs, 1989
- A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk PatientsNew England Journal of Medicine, 1989
- Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.Journal of Clinical Investigation, 1988
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957